Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Why Shares of Blueprint Medicines Are Falling Wednesday
01:00pm, Wednesday, 02'nd Aug 2023
Blueprint Medicines announced increased revenue and decreased losses. The company's lead therapy, Ayvakit, is now approved for three indications.
Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:12am, Wednesday, 02'nd Aug 2023
Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with W
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
08:00am, Wednesday, 19'th Jul 2023
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
09:30am, Monday, 12'th Jun 2023
Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements.
This Biotech Could Soon Go Parabolic, But Should You Buy It?
08:45am, Sunday, 04'th Jun 2023
Blueprint Medicines just got a critical green light from regulators for Ayvakit. This treats a rare and often debilitating blood disorder affecting 1 in 10,000 people.
Blueprint Is Well-Positioned To Capitalize On ISM Market (Maintain 'Buy')
02:28am, Tuesday, 09'th May 2023
Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multiple ongoing programs. The company's stock has risen
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up
08:23am, Friday, 05'th May 2023
Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
10:32am, Friday, 17'th Feb 2023
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Call Transcript
02:27pm, Thursday, 16'th Feb 2023
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Havi
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Thursday, 16'th Feb 2023
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
01:33pm, Monday, 13'th Feb 2023
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Blueprint Medicines: A Slow But Steady Blueprint For Success
01:34pm, Wednesday, 14'th Dec 2022
Blueprint Medicines Corporation has multiple approved drugs and potential label expansions. Sales have not been as good as expected.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
12:03pm, Wednesday, 23'rd Nov 2022
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
12:03pm, Wednesday, 02'nd Nov 2022
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
03:10pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
